Skip to main content

Press releases

2024-09-13
Moberg Pharma AB (OMX: MOB) announces that the company has received information about clinical cure in a subset of patients in the ongoing North American Phase 3 study for MOB-015 against nail fungus. The number of patients who have achieved clinical cure in this blinded subset of patients is lower than the company's expectations, which necessitates that Moberg Pharma inform the market about this fact.
2024-08-13
TERCLARA IS THE MARKET LEADER IN SWEDEN
2024-07-31
Moberg Pharma AB (publ) (the “Company”) today announces that the number of ordinary shares in the Company has increased to a total of 47,879,854 due to the directed issue of 863,333 ordinary shares to the investors who had entered into top guarantee commitments in connection with the exercise warrants of series 2023:1 (TO 2) (the “Share Issue”).
2024-06-28
Moberg Pharma AB (publ) (the “Company”) today announces that the number of ordinary shares in the Company has increased to a total of 47,016,521 due to the exercise of warrants of series 2023:1 (“TO 2”) and due to the issue of C-shares which subsequently were converted into ordinary shares and repurchased by the Company to secure the Company's commitments under incentive programmes.
2024-06-24
(“Moberg Pharma” or the “Company”) announces that 17,776,856 warrants of series 2023:1 (“TO 2”) were exercised for subscription of in total 17,776,856 ordinary shares for approximately SEK 320 million, corresponding to a subscription rate of approximately 98%. As announced by the Company on June 11[th], 2024, subscription and top guarantee commitments had been made for TO 2, free of charge, with certain external professional investors, and today the board of directors has resolved on a directed issue of 863,333 ordinary shares amounting to approximately SEK 16 million to the top guarantors to fulfil the top guarantee commitments (the “Share Issue”). Through the exercise of TO 2 and the Share Issue, Moberg Pharma thus receives approximately SEK 336 million before issue costs.
2024-06-17
Today, June 17[th], 2024, is the last day for trading in Moberg Pharma AB's (publ)'s ("Moberg Pharma" or the "Company") warrants of series 2023:1 (“TO 2”). The exercise period runs until June 19[th], 2024.
2024-06-11
Moberg Pharma AB (publ) (“Moberg Pharma” or the “Company”) has today received subscription intentions, subscription commitments and top guarantee commitments totaling approximately SEK 113.5 million, related to the warrants of series 2023:1 (“TO 2”), from a few external professional investors and the Company's largest shareholder, Östersjöstiftelsen (The Baltic Sea Foundation).
2024-06-05
Today, the exercise period for Moberg Pharma AB (publ)'s ("Moberg Pharma" or the "Company") warrants of series 2023:1 begins. The exercise period runs during the period from and including June 5[th], 2024, up to and including June 19[th], 2024. The last day for trading in warrants of series 2023:1 on Nasdaq Stockholm is June 17[th], 2024.
2024-05-31
Moberg Pharma AB (publ) ("Moberg Pharma" or the "Company") today announces that the subscription price for ordinary shares upon exercise of warrants of series 2023:1 is SEK 18.00 per ordinary share. The exercise period begins on June 5[th], 2024, and runs until June 19[th], 2024. The last day for trading in warrants of series 2023:1 on Nasdaq Stockholm is June 17[th], 2024.
2024-05-24
Moberg Pharma AB (publ) today announces that the board of directors exercises authorizations to issue and repurchase C-shares, and converts C-shares to common shares, to secure the company’s commitments under incentive programmes and for the purpose of covering certain costs that may arise as a result of incentive programs.
2024-05-20
Moberg Pharma AB (OMX: MOB) announces that Terclara[®] is the market leader in Sweden for the month of April, the first full month the product is available with promotion. The aim for the launch in Sweden was to achieve a market-leading position, which has already been accomplished.
2024-05-14
STOCKHOLM, May 14[th], 2024. Moberg Pharma AB (publ)’s (“Moberg Pharma” or the “Company”) Annual General Meeting took place today. The Annual General Meeting resolved in accordance with the Nomination Committee’s and Board of Directors’ proposals as set out below.
2024-05-07
LAUNCH INITIATED IN SWEDEN
2024-05-06
STOCKHOLM, May 6[th], 2024, Moberg Pharma AB (OMX:MOB) hereby announces that MOB-015 has received national approvals for all countries included in the decentralized procedure. MOB-015 is thus approved for the treatment of mild to moderate fungal infections of the nails in adults in 13 European countries.
2024-04-23
STOCKHOLM, April 23[rd], 2024, Moberg Pharma AB (OMX:MOB) reports strong interest from pharmacists, physicians and end customers in the launch of MOB-015 under the brand Terclara[®] in Sweden. A majority of Swedish pharmacies now have the product available on the shelf.
2024-04-12
Shareholders in Moberg Pharma AB (publ), reg. no. 556697-7426, (the “Company”) are hereby convened to the Annual General Meeting on 14 May 2024 at 14:00 at Advokatfirman Schjødt, Hamngatan 27 in Stockholm.
2024-04-12
Moberg Pharma´s Annual report for 2023 has been published and is available on www.mobergpharma.se
2024-04-08
STOCKHOLM, April 8[th], 2024, Moberg Pharma AB (OMX:MOB) has submitted an application to include the proposed terbinafine supplier in the company's registration dossier for its nail fungus drug MOB-015. Approval is expected before the end of the year.
2024-02-19
STOCKHOLM, February 19[th], 2024. Moberg Pharma AB (OMX: MOB) announces that the company’s Nomination Committee has decided to present the following proposal to the Annual General Meeting 2024.
2024-02-13
LAUNCH INITIATED IN SWEDEN
2024-02-07
STOCKHOLM, February 7[th], 2024, Moberg Pharma ABs (OMX: MOB) marker partner in Sweden – Allderma AB, a company which specialises in the sale of over-the-counter (OTC) pharmaceuticals – has now launched sales of MOB-015 under the Terclara[®] brand. The interest among pharmacies has been significant for Moberg Pharma's medication against nail fungus.
2023-11-07
MOB-015 HAS RECEIVED NATIONAL APPROVALS IN 10 EU COUNTRIES, ANOTHER 3 APPROVALS ARE EXPECTED
2023-11-07
STOCKHOLM, November 7[th], 2023, Moberg Pharma AB (OMX: MOB) is strengthening its organization following market approval earlier this year and in preparation for the upcoming launch. The management team is welcoming two new members, Christina Erixon, Head of Pharmaceutical Development & Operations, who is replacing Agneta Larhed, and Robert Ehrl, Head of Supply, who is taking over from Jesper Lind. Both roles have been expanded from part-time consultants to full-time positions.
2023-10-17
STOCKHOLM, October 17[th], 2023 – In accordance with the resolution of the Annual General Meeting on May 16[th], 2023, the Chairman of the Board has contacted the company’s two largest shareholders or group of shareholders in terms of votes to form a Nomination Committee. These shareholders have been invited to appoint one representative each who, together with the Chairman of the Board, will comprise the Nomination Committee. As not all of the company’s two largest shareholders or group of shareholders have wished to appoint such representative, the third largest shareholder/group of shareholders have been invited to appoint one representative and so on until the Nomination Committee now comprises of three members, in accordance with the resolution of the Annual General Meeting on May 16[th], 2023.
2023-10-09
STOCKHOLM, 9 October 2023. Moberg Pharma AB (publ)’s (OMX: MOB) (the “Company”) Extraordinary General Meeting took place today. The Extraordinary General Meeting resolved to approve the Board of Directors' resolution to issue warrants.
2023-10-06
STOCKHOLM, October 6[th], 2023, Moberg Pharma AB (OMX: MOB) has completed the recruitment of 384 patients with onychomycosis (nail fungus) for the ongoing MOB-015 phase 3 study in North America. The aim is to provide a pivotal part of the clinical data set for registration and commercialization of MOB-015 in the U.S.. Topline results are expected in January 2025.
2023-09-29
Moberg Pharma AB (publ) (the "Company") today announces that the number of shares in the Company has increased to a total of 28,407,452 due to the completion of the rights issue of units, consisting of ordinary shares and warrants of series 2023:1, resolved by the Board of Directors on 28 June 2023 (the "Rights Issue") and due to the completion of the directed issue of units, consisting of ordinary shares and warrants of series 2023:1, to guarantors in the Rights Issue who chose to receive their guarantee commission in the form of units (the "Remuneration Issue").
2023-09-13
Shareholders in Moberg Pharma AB (publ), reg. no. 556697-7426 (the “Company”), are hereby convened to the Extraordinary General Meeting on 9 October 2023 at 09:30 on Advokatfirman Schjødt, Hamngatan 27 in Stockholm.
2023-09-13
STOCKHOLM, 13 September 2023. As announced on 8 September 2023, the Board of Directors of Moberg Pharma AB (publ) (OMX: MOB) ("Moberg Pharma" or the "Company") the same day decided that 664,370 units, corresponding to 664,370 ordinary shares and 664,370 warrants of series 2023:1, shall be issued to the guarantors in the rights issue of units resolved upon by the Board of Directors on 28 June 2023 and approved by the Extraordinary General Meeting on 8 August 2023 (the "Rights Issue") who have chosen to receive their guarantee commission in the form of newly issued units in Moberg Pharma (the "Remuneration Issue"). In the press release that was issued on 8 September 2023, it was stated that the resolution on the Remuneration Issue was made by virtue of the authorization granted by the Annual General Meeting on 16 May 2023. Moberg Pharma today clarifies that the resolution to issue the new ordinary shares in the Remuneration Issue was made by virtue of the authorization granted by the Annual General Meeting on 16 May 2023, while the resolution to issue the warrants in the Remuneration Issue was made conditional on the subsequent approval of the general meeting of shareholders. A notice to an Extraordinary General Meeting on 9 October 2023 containing the proposal to approve the Board of Directors' resolution to issue the 664,370 warrants of series 2023:1 included in the Remuneration Issue will be announced through a separate press release shortly.
2023-09-08
STOCKHOLM, 8 September 2023. The Board of Directors of Moberg Pharma AB (publ) (OMX: MOB) ("Moberg Pharma" or the "Company") has today, by virtue of the authorization granted by the Annual General Meeting on 16 May 2023, resolved on a directed new issue of 664,370 units, corresponding to 664,370 ordinary shares and 664,370 warrants of series 2023:1, to the guarantors in the rights issue of units resolved upon by the Board of Directors on 28 June 2023 and approved by the Extraordinary General Meeting on 8 August 2023 (the "Rights Issue") who have chosen to receive their guarantee commission in the form of newly issued units in Moberg Pharma (the "Remuneration Issue"). The subscription price in the Remuneration Issue amounts to SEK 7.27, which corresponds to the volume-weighted average price of the Company's share on Nasdaq Stockholm during the subscription period in the Rights Issue, and payment is made by set-off of claims.
2023-09-01
STOCKHOLM, 1 September 2023. The Board of Directors of Moberg Pharma AB (publ) (OMX: MOB) (“Moberg Pharma” or the “Company”) today announces the outcome of the rights issue of units, consisting of ordinary shares and warrants, with preferential rights for Moberg Pharma’s shareholders (the “Rights Issue”) which was resolved upon by the Board of Directors on 28 June 2023 and approved by an Extraordinary General Meeting on 8 August 2023. The outcome of the Rights Issue shows that subscription with support of unit rights and applications for subscription of units without support of unit rights in total correspond to approximately 130 percent of the units offered for subscription. 16,130,585 units were subscribed for with support of unit rights, corresponding to approximately 92 percent of the Rights Issue. Additionally, applications for subscription of 6,565,433 units without support of unit rights have been received, corresponding to approximately 38 percent of the Rights Issue. Consequently, persons who only applied for subscription of units without support of unit rights will not be allocated units in the Rights Issue. Thus, the Rights Issue is fully subscribed, and no issue guarantors are used. Moberg Pharma will receive approximately SEK 100 million before deduction for transaction costs.
2023-08-14
Moberg Pharma AB (publ) (OMX: MOB) (“Moberg Pharma” or the “Company”) announces that the prospectus relating to the Company’s rights issue of units consisting of ordinary shares and warrants (the “Rights Issue”) has been approved and registered by the Swedish Financial Supervisory Authority and is available in Swedish on the Company’s website www.mobergpharma.se/investerare/prospekt and will also be available on the Swedish Financial Supervisory Authority’s website, www.fi.se.
2023-08-08
STOCKHOLM, 8 August 2023. Moberg Pharma AB (publ)’s (OMX: MOB) (the “Company”) Extraordinary General Meeting took place today. The Extraordinary General Meeting resolved as set out below.
2023-08-07
CORRECTION: STOCKHOLM, 7 August 2023. Due to technical issuing details at Euroclear Sweden AB, a correction has been made in relation to the final terms published on 4 August 2023, with a change regarding the number of unit rights shareholders are allocated per existing ordinary share and the number of units the unit rights entitle to. The correction does not affect the subscription price or transaction size.
2023-08-04
STOCKHOLM, 4 August 2023. On 28 June 2023, the Board of Directors of Moberg Pharma AB (publ) (OMX: MOB) (“Moberg Pharma” or the “Company”) announced that the Board of Directors had resolved to, subject to the approval of the Extraordinary General Meeting to be held on 8 August 2023 (the “EGM”), carry out a rights issue of ordinary shares and warrants (“Units”) with preferential rights for existing shareholders in the amount of approximately MSEK 100 before transaction costs (the “Rights Issue”). The Board of Directors of Moberg Pharma today announces the final terms of the Rights Issue. Existing shareholders in Moberg Pharma as of the record date, 14 August 2023, will receive eight (8) unit rights per one (1) existing ordinary share. Nine (9) unit rights entitle to subscription of two (2) Units in the Rights Issue. Each Unit consist of one (1) ordinary share and one (1) warrant issued without cost. The subscription price is SEK 5.75 per Unit. In addition, the Board of Directors has resolved to withdraw three of the four alternative proposals for amendments to the Articles of Association which the Board of Directors previously had submitted to the EGM.
2023-08-04
STOCKHOLM, August 4[th], 2023, Moberg Pharma AB (OMX:MOB) hereby announces that MOB-015 has received national approval for the company’s home market, Sweden, for the treatment of mild to moderate fungal infections of the nails in adults. This is the second country to grant national approval for MOB-015, following the approval in Ireland announced July 31[st], and Sweden is the first country where MOB-015 has been approved for over-the-counter (OTC) use.
2023-08-03
MOB-015 IS RECOMMENDED FOR APPROVAL IN 13 EUROPEAN COUNTRIES
2023-07-31
STOCKHOLM, July 31[st], 2023, Moberg Pharma AB (OMX:MOB) hereby announces that MOB-015 has received national approval in Ireland for the treatment of mild to moderate fungal infections of the nails in adults. Ireland is the first country to grant market authorization for Moberg Pharma´s new onychomycosis treatment after the Decentralized Procedure concluded with a positive outcome, where MOB-015 was recommended for national approval in 13 European countries, see press release from June 28[th] 2023.
2023-06-30
STOCKHOLM, June 30[th], 2023, Moberg Pharma AB (publ) announced that the total number of common shares in the company has increased to 10,272,933. The 187,000 newly issued shares are held by the company to secure its commitments under incentive programmes.
2023-06-28
Shareholders in Moberg Pharma AB (publ), reg. no. 556697-7426 (the “Company”), are hereby convened to the Extraordinary General Meeting at 8 August 2023 at 14:00 on Advokatfirman Schjødt, Hamngatan 27 in Stockholm.